SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
Pictured: Office building science collage
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
October 3, 2024
 · 
1 min read
 · 
Angela Gabriel
3D illustration of an antibody-drug conjugate
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble
Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely complicates regulatory discussions for approval of this indication,” Jefferies analyst Peter Welford wrote in a note to investors.
September 23, 2024
 · 
3 min read
 · 
Tristan Manalac
Tumor microenvironment concept with cancer cells, T-Cells, nanoparticles, cancer associated fibroblast layer of tumor microenvironment normal cells, molecules, and blood vessels 3d rendering
Cancer
ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer treatment—antibody-drug conjugates, bispecifics and radiopharmaceuticals—while anti-TIGIT therapies made a bit of a comeback.
September 20, 2024
 · 
3 min read
 · 
Greg Slabodkin
3D illustration of an antibody-drug conjugate
Antibody-drug conjugate (ADC)
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.
September 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells 3d rendering
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo’s Dato-DXd Fails to Significantly Improve Overall Survival in Phase III NSCLC
Despite the disappointing late-stage results in non-small cell lung cancer, Jefferies analyst Stephen Barker contends the likelihood of FDA approval “remains high” for the experimental antibody-drug conjugate, though the regulator is now more likely to convene an advisory committee.
September 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo Turn to AI to Explain Phase III NSCLC Miss for Dato-DXd
Using a computational biomarker, the companies say they can identify which patients would derive significant clinical benefit from their experimental antibody-drug conjugate. AstraZeneca and Roche are co-developing and commercializing a companion diagnostic for the biomarker.
September 9, 2024
 · 
2 min read
 · 
Tristan Manalac
South San Francisco, CA, USA - May 1, 2022: Exterior view of the Merck Researches Laboratories in South San Francisco, California. Merck & Co., Inc. is a global pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme (MSD) outside the United States and Canada.
Deals
Daiichi Pays Merck $170M for T-Cell Engager, Expands ADC Partnership
After dropping $4 billion on a deal with the Japanese company last year, Merck is getting back some of its investment as Daiichi Sankyo buys into a Phase I/II T-cell engager therapy acquired from Harpoon Therapeutics.
August 6, 2024
 · 
1 min read
 · 
Kate Goodwin
Podcasts
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
Two CRLs from the FDA last week cited concerns with third-party manufacturers, while Indian CDMOs may make a bid for U.S. business if there is a decoupling from Chinese companies under the BIOSECURE Act.
July 3, 2024
 · 
1 min read
 · 
Jef Akst
Business partners discussing the terms of a contract
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
October 1, 2024
 · 
19 min read
Press Releases
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
October 1, 2024
 · 
19 min read
Press Releases
Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
September 27, 2024
 · 
9 min read
Press Releases
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
September 23, 2024
 · 
19 min read
Press Releases
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
September 16, 2024
 · 
7 min read
Drug Development
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
June 2, 2024
 · 
39 min read
Business
RevolKa Signed Master Service Agreement with Daiichi Sankyo
May 27, 2024
 · 
2 min read
Drug Development
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
May 27, 2024
 · 
8 min read
Pharm Country
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
May 21, 2024
 · 
9 min read
Business
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
April 29, 2024
 · 
33 min read
Load More